A recent study led by Hidenori Machino at the RIKEN Center for Advanced Intelligence Project (AIP) and the National Cancer Center Research Institute in Japan used a big data multi-omics analysis to examine changes in gene expression as cells from human fallopian tubes become cancerous.
Gilead stops last PhIII of CD47 drug, citing FDA hold, higher risk of death in treatment arm
Gilead discontinued its remaining Phase III study of magrolimab, an anti-CD47 antibody that the company was testing for acute myeloid leukemia and its precursor disease,
February 8, 2024